{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of pancreatic cancer" in comments (approximate match)
Status:
Investigational
Source:
INN:ixotatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ulenistamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:tecotabart vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01395745: Phase 3 Interventional Completed Systemic Lupus Erythematosus
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02399137: Phase 2 Interventional Completed Pancreatic Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02923921: Phase 3 Interventional Completed Pancreatic Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:perenostobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02829099: Phase 1 Interventional Completed Advanced Solid Neoplasms
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04019288: Phase 1/Phase 2 Interventional Completed Platinum-Resistant Fallopian Tube Carcinoma
(2019)
Source URL:
Class:
PROTEIN